文献速递湿疹皮炎与荨麻疹

特应性皮炎新兴疗法:前列腺素/白三烯通路

Emerging therapies for atopic dermatitis: The prostaglandin/leukotriene pathway.
PubMed 文献 · J Am Acad Dermatol · 2017-12-15

本文综述前列腺素和白三烯在特应性皮炎发病中的作用及相关靶向治疗进展。孟鲁司特疗效存疑,齐留通小规模试验有临床改善;OC000459临床试验未显效,Q301和ZPL-521疗效待验证。若成功, topical制剂可能用于慢性维持和预防复发。

要点

  • 白三烯和前列腺素在特应性皮炎中具病理生理作用。
  • 孟鲁司特疗效存疑,齐留通小规模试验有改善。
  • OC000459未显效,Q301和ZPL-521疗效待验证。

核心结论

  • 靶向前列腺素/白三烯通路的药物可能对特应性皮炎有治疗潜力,但现有证据有限。

研究设计与样本

  • 综述性文章,未报告系统检索范围或样本量。

主要发现

  • 孟鲁司特在特应性皮炎患者中疗效存疑。
  • 齐留通小规模试验显示部分临床显著改善。
  • OC000459在临床试验中未显示疗效。
  • Q301和ZPL-521的疗效尚待确定。

临床怎么用

  • 若这些药物被证实有效,局部制剂可能用于特应性皮炎的慢性维持治疗和预防复发。

局限性

  • 未报告综述的检索策略、纳入标准或证据质量评价。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The role of leukotrienes and prostaglandins in development of atopy has been prototypically established in studies of asthma pathogenesis. Likewise, both in vitro and in vivo studies of atopic dermatitis have demonstrated that these molecules maintain important pathophysiologic roles. Thus, it follows that targeted therapies against these molecules may be promising in management of atopic dermatitis. Montelukast has had questionable efficacy in patients with atopic dermatitis, whereas small pilots using zileuton did have some clinically significant improvement. There are several agents in development that target leukotrienes and/or prostaglandins as well, including OC000459, Q301, and ZPL-521. In atopic dermatitis, OC000459 did not demonstrate efficacy in clinical trials, and the efficacy of the other 2 agents remains to be seen. Should these medications prove promising, these topical agents may play a future role in chronic maintenance therapy and flare prophylaxis in atopic dermatitis, as antileukotriene therapy does in asthma.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Yanes DA, Mosser-Goldfarb JL. Emerging therapies for atopic dermatitis: The prostaglandin/leukotriene pathway. J Am Acad Dermatol. 2017. PMID: 29248523. doi:10.1016/j.jaad.2017.12.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。